Drugs / CR059
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07347080 | Jan → Aug 2026 overdue | type 2 diabetes mellitus | The First Affiliated Hospital of Henan University of Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CR059 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07347080 ↗ |
| Known as | Exenatide | “Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059)” NCT07347080 ↗ |
| Modality | Other / unclassified | “Circular RNA” NCT07347080 ↗ |